Table 2 A Univariate survival analysis (OS and DSS) considering L1CAM among ProMisE subgroups. B Multivariate survival analysis (OS and DSS) considering L1CAM, age and ProMisE subgroups
From: L1CAM further stratifies endometrial carcinoma patients with no specific molecular risk profile
OS | DSS | |||||
|---|---|---|---|---|---|---|
# of events / n | Hazard ratio (95% CI) | LRT P value | # of events / n | Hazard ratio (95% CI) | LRT P value | |
A | ||||||
POLE | ||||||
L1CAM negative (ref) | 5/42 | — | 1/42 | — | ||
L1CAM positive | 1.39 (0.07–9.45) | 0.7 | NA | 0.06 | ||
P53 wt/NSMP | ||||||
L1CAM negative (ref) | 41/228 | — | 16/227 | — | ||
L1CAM positive | 3.78 (1.69–7.61) | 0.002 | 7.82 (2.65–21.12) | 0.001 | ||
MMR-D | ||||||
L1CAM negative (ref) | 33/127 | — | 16/126 | — | ||
L1CAM positive | 1.25 (0.53–2.66) | 0.6 | 1.26 (0.35–3.63) | 0.7 | ||
P53 abn | ||||||
L1CAM negative (ref) | 33/55 | — | 22/55 | — | ||
L1CAM positive | 0.87 (0.39–2.17) | 0.7 | 1.06 (0.40–3.68) | 0.9 | ||
B | ||||||
Age | 112 / 452 | 55 / 450 | ||||
34.16 (10.16–117) | <0.001 | 4.61 (0.83–25.67) | 0.08 | |||
ProMisE | 112 / 452 | 55 / 450 | ||||
p53 wt/NSMP (ref) | — | — | ||||
POLE | 0.84 (0.28–1.95) | <0.001 | 0.32 (0.02–1.61) | 0.002 | ||
MMR-D | 1.49 (0.93–2.38) | 1.73 (0.86–3.46) | ||||
p53 abn | 3.18 (1.71–5.97) | 3.97 (1.74–9.31) | ||||
L1CAM status | 112 / 452 | 55 / 450 | ||||
Negative (ref) | — | — | ||||
Positive | 1.33 (0.77–2.22) | 0.3 | 2.05 (1.00–4.10) | 0.05 | ||
